drug
KEYTRUDA QLEX
updated 6mo agoby Merck Sharp & Dohme LLC
community read0 votes
🐶 often sniffed alongside
top 8- drugpembrolizumab269 co-mentions · 131 sources
- drugKEYTRUDA269 co-mentions · 131 sources
- tagApproval266 co-mentions · 128 sources
- drugCancer Program133 co-mentions · 128 sources
- drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
- tagGlioblastoma2 co-mentions · 1 sources
- tagOncology1 co-mentions · 1 sources
- tagNeurology1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying KEYTRUDA QLEX
- phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- phase3A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase2A Study of DS-3939a in Participants With Solid Tumors
- phase3A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
News(10)
- Keytruda biosimilars are coming — but they face an uphill battleA patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.biopharma_dive · 14d ago
- Merck looks ahead to ‘another year of investment’ as Keytruda cliff loomsOn its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertensi…biospace · 18d ago
- Merck outlines 2027 as ‘another year of investment’ despite recent clinical winsEven as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…fiercebiotech · 19d ago
- Opinion: Cancer vaccines are finally here. How do we get them to patients?“If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman Laraki.stat · 21d ago
- ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leakAfter sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last w…biospace · 21d ago
- ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine dataMerck & Co. and Moderna always knew they would make headlines in Madrid this week—just not in the way it happened.fiercebiotech · 24d ago
- Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earningsBellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.biospace · 1mo ago
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialA Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.biopharma_dive · 1mo ago
- The signal that changes everything: understanding MRD in oncology drug developmentIs the cancer truly gone?fiercebiotech · 2mo ago
- Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerInhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.biospace · 2mo ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that